MORF Insider Trading

Notice: This stock is marked as potentially delisted. It may not be actively trading.
Insider Ownership Percentage: 25.60%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $7,018,566.18

Morphic Insider Trading History Chart

This chart shows the insider buying and selling history at Morphic by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$40M-$20M$0$20M$40MTotal Insider BuyingTotal Insider Selling

Morphic Share Price & Price History

Current Price: $56.99
Price Change: +0.30 (1.20%)
As of 08/16/2024 01:00 AM ET

This chart shows the closing price history over time for MORF up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table

SEC Filings (Institutional Ownership Changes) for Morphic (NASDAQ:MORF)

94.25% of Morphic stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at MORF by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$200M-$100M$0$100M$200MTotal InflowsTotal Outflows
Morphic logo
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidate MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation is in Phase 2 clinical trials for the treatment of inflammatory bowel disease. The company's products in pipeline include Next Gen a4ß7 Inhibitors for additional potential GI indications, such as EGIDs, pouchitis, etc.; avß8 for the treatment of Myelofibrosis and solid tumor; and fibronectin integrin for pulmonary hypertensive. In addition, it has a license agreement with Janssen to discover and develop novel integrin therapeutics; collaboration agreement with Schrödinger for integrin targets; and license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. Morphic Holding, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.
Read More on Morphic

Today's Range

Now: $56.99
Low: $56.99
High: $56.99

50 Day Range

MA: $56.76
Low: $55.74
High: $56.99

52 Week Range

Now: $56.99
Low: $19.34
High: $57.00

Volume

400 shs

Average Volume

1,272,131 shs

Market Capitalization

$2.85 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.49

Who are the company insiders with the largest holdings of Morphic?

Morphic's top insider shareholders include:
  1. Timothy A Springer (Director)
  2. Bruce Rogers (President)
  3. Praveen P Tipirneni (CEO)
  4. Marc Schegerin (CFO)
  5. Robert E Farrell Jr (CAO)
  6. William Devaul (General Counsel)
  7. Joseph P Slattery (Director)
Learn More about top insider investors at Morphic.